# Multicenter evaluation: Predictors for *Pseudomonas aeruginosa* surgical site infections after head/neck cancer microvascular reconstruction

dress correspondence to:
Susan L. Davis, PharmD
sldavis@wayne.edu
WAYNE STAT



Veve MP<sup>1, 2</sup>, Greene JB<sup>1</sup>, Williams AT<sup>1</sup>, Ghanem TA<sup>1</sup>, Davis SL<sup>1, 2</sup> for the Head and Neck Cancer Research Group <sup>1</sup>Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA; <sup>2</sup>Henry Ford Hospital, Detroit, MI, USA

# Introduction

Surgical site infections (SSI) in head/neck cancer microvascular reconstruction remain a significant post-operative complication, despite the increased use of post-operative antibiotic prophylaxis (POABP). The role of *Pseudomonas aeruginosa* (PSA) SSI in this population has not been well established, but perceived PSA risk factors are extrapolated from traditional variables found in other disease states (e.g. immunosuppression, diabetes). Consequently, some clinicians prefer to use antipseudomonal POABP in this setting. Optimal POABP durations are also unknown, and combined with overuse of extended spectrum antimicrobials, can lead to poor outcomes, selection for resistant organisms, or severe adverse reactions (e.g. *Clostridioides difficile*-associated diarrhea).

The objective of this study was to characterize SSI microbiology and identify PSA risk factors for patients who receive head/neck cancer microvascular reconstruction among eleven North American institutions.

# **Methods**

### Study Design

This was an IRB approved cross sectional study with a nested case-case-control, conducted at eleven North American tertiary-care centers.

### **Study Population**

The study population included hospitalized patients who received head/neck cancer microvascular reconstruction from January 2003 to December 2015.

| Inclusion   | n Criteria       | Exclusion Criteria   |
|---|------------------|--|
| <ul> <li>Age ≥ 18 years</li> <li>Documented of</li> </ul> | ncologic disease | <ul> <li>Patients with existing infection prior to surgery</li> <li>Patients requiring an infection-related operating room visit within 48-hours post-operation of initial surgery</li> <li>Surgical intervention on an existing tumor within 90-days prior to microvascular reconstruction</li> </ul> |

### **Data Collection**

Data collected included: patient demographics (e.g. American Society of Anesthesiologists [ASA] classification system), select comorbid conditions (e.g. diabetes mellitus, smoking and alcohol status, previous radiation therapy), surgery and infection characteristics (POABP spectrum and durations, 30-day SSI per CDC/NHSN criteria, unexpected return to operating room), and SSI microbiology. All species identification was completed by individual institution in accordance to Clinical & Laboratory Standards Institute (CLSI) standards. Data were collected using a standardized electronic case report form.

### **Key Definitions**

POABP was categorized *a priori* based on bacterial spectrum of activity, as determined by blinded infectious diseases pharmacists:

**Narrow**: Gram-positive with anaerobic coverage only

**Broad**: Gram-positive, enteric Gram-negative, and anaerobic coverage

Antipseudomonal: Gram-positive, anti-pseudomonal, and anaerobic coverage

### **Statistical Analyses**


Descriptive statistics were used to identify the incidence of 30-day SSI. Baseline patient characteristics were compared using bivariate analyses: categorical variables were compared by the Pearson's  $\chi^2$  or Fisher's exact test, continuous variables were compared by the student's *t*-test or the Mann-Whitney U-test; *P*-values <0.05 were considered statistically significant. Cases were defined as patients with PSA SSI and with non-PSA SSI; controls were patients without SSI. Multiple comparisons were performed in case-case-control fashion. All statistics were performed using IBM SPSS Statistics version 23.0.

### **Acknowledgments:**

Contributors to the Head and Neck Cancer Research group this study included: Mark K. Wax (Oregon Health & Science University), Jeremy D. Richmon (Johns Hopkins University), Ryan S. Jackson (Washington University in St. Louis), Urjeet A. Patel (Northwestern University), Joshua D. Hornig (Medical University of South Carolina), Matthew M. Hanasono (University of Texas MD Anderson Cancer Center), Lisa Shnayder (Kansas University School of Medicine), Matthew Old (Ohio State University).

# Patient and Antibiotic Characteristics

| Covariate n (%) or median (IQR) | <i>n</i> = 1307 |
|---------------------------------|-----------------|
| Median age, years               | 62 (53-70)      |
| Sex, male                       | 894 (68%)       |
| Diabetes mellitus               | 205 (16%)       |
| Previous radiation therapy      | 452 (35%)       |
| Smoking status, current         | 375 (29%)       |
| Median surgery duration, hrs    | 9.6 (7.9-12.1)  |




Results

\*The median [IQR] duration of all POABP was 6 days [3-7]

Covariate

## **Infection Characteristics**

### Surgical Site Incidence per Year



| (C              |         |            |            |            |            |            |            |            |            |            |            |            |
|-----------------|---------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|
|                 | Pre-'04 | <b>'05</b> | <b>'06</b> | <b>'07</b> | <b>'08</b> | <b>'09</b> | <b>'10</b> | <b>'11</b> | <b>'12</b> | <b>'13</b> | <b>'14</b> | <b>'15</b> |
| Surgeries/year  | 1       | 87         | 78         | 33         | 13         | 33         | 202        | 200        | 104        | 186        | 214        | 156        |
| Infections/year | 0       | 8          | 3          | 0          | 6          | 6          | 22         | 28         | 21         | 17         | 45         | 33         |

| 30-day SSI                  | 189 (15%)   |
|-----------------------------|-------------|
| Time to SSI, days           | 11.5 (7-17) |
| Unexpected 30-day OR return | 261 (20%)   |

n (%) or median (IQR)

# Microbiology

• P. aeruginosa was isolated from 17 (9%) of the 189 patients who developed 30-day SSI

# SSI Cultures, n = 189 Gram-positive, single organism Gram-negative, single organism Gram-negative, single organism Gram-negative, polymicrobial Polymicrobial, mixed Polymicrobial, other Other cx No/negative cx

# Individual Isolates (including polymicrobial), n = 175 3% 6% Enterococcus sp. Methicillin-resistant S. aureus Methicillin-susceptible S. aureus Streptococcus sp. Other Gram-positives P. aeruginosa Other Gram-negatives Anaerobes Candida sp. Other organisms

# Comparison of Post-operative Antibiotic Prophylaxis

| Covariate n (%) or median (IQR) | Narrow<br><i>n</i> = 125 | Broad<br>n = 565 | Antipseudomonal<br>n = 309 | <i>P</i> -value* |
|---------------------------------|--------------------------|------------------|----------------------------|------------------|
| Median age, years               | 62 (52-69)               | 61 (53-71)       | 63 (55-71)                 | 0.63             |
| Sex, Male                       | 72 (58%)                 | 402 (71%)        | 210 (68%)                  | 0.005            |
| 30-day chemotherapy use         | 6 (5%)                   | 48 (9%)          | 35 (11%)                   | 0.09             |
| ASA Classification ≥ III        | 96 (77%)                 | 446 (79%)        | 293 (95%)                  | 0.02             |
| Diabetes mellitus               | 14 (11%)                 | 88 (16%)         | 57 (18%)                   | 0.12             |
| Previous radiation therapy      | 42 (34%)                 | 190 (34%)        | 109 (35%)                  | 0.89             |
| Smoking status, current         | 29 (23%)                 | 172 (30%)        | 96 (31%)                   | 0.09             |
| Alcohol intake, current         | 56 (45%)                 | 252 (45%)        | 118 (38%)                  | 0.6              |
| Median POABP duration, days     | 3 (1-7)                  | 5 (3-7)          | 7 (5-8)                    | < 0.001          |
| 30-day SSI                      | 44 (35%)                 | 80 (14%)         | 61 (20%)                   | < 0.001          |

\*Narrow POABP used as reference group

# Risk Factors for *P. aeruginosa* Surgical Site Infections

| Covariate                  | PSA SSI to non-PSA SSI<br>UnadjOR (95% CI) | PSA SSI to controls<br>UnadjOR (95% CI) |
|----------------------------|--|---|
| ASA Classification ≥ III   | 2.8 (0.36-22.4)                            | 3.2 (0.43-24.4)                         |
| Previous radiation therapy | 1.8 (0.66-4.9)                             | 1.7 (0.64-4.4)                          |
| Smoking status, current    | 0.56 (0.18-1.8)                            | 0.8 (0.26-2.5)                          |
| Alcohol intake, current    | 0.76 (0.27-2.1)                            | 0.74 (0.27-2.0)                         |
| Diabetes mellitus          | 0.75 (0.16-3.47)                           | 0.71 (0.16-3.1)                         |
| Antipseudomonal POABP      | 0.59 (0.19-1.9)                            | 0.70 (0.22-2.2)                         |

# Summary

- P. aeruginosa was uncommonly isolated from surgical site infections
- Antipseudomonal POABP spectrum and other traditional risk factors were also not associated with P. aeruginosa surgical site infections
- Antimicrobial stewardship interventions that limit unnecessary exposure to antimicrobials can have beneficial outcomes for patients and prevent the emergence of resistant organisms